Holen Sie sich die Stockscreener-App
33.19
7.00%
2.17
Handel nachbörslich:
33.19
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 7.2%What's Next? - MarketBeat
STOK: BTIG Reiterates Buy Rating with $39 Price Target | STOK St - GuruFocus
Stoke Therapeutics' (STOK) Buy Rating Reiterated at BTIG Research - MarketBeat
Stoke Therapeutics earnings missed by $0.21, revenue fell short of estimates - Investing.com Canada
Stoke Therapeutics (NASDAQ: STOK) launches $150M ATM sales agreement with Cantor - Stock Titan
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 17, 2026 - BioSpace
Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop? - Kalkine Media
Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative - simplywall.st
STOK: Wedbush Raises Price Target for Stoke Therapeutics | STOK Stock News - GuruFocus
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 605 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) chief patient officer exercises 10,000 RSUs into shares - Stock Titan
Stoke Therapeutics (STOK) CFO exercises 14,750 RSUs, now holding 14,750 shares - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CMO exercises 33,850 RSUs - Stock Titan
Stoke Therapeutics (STOK) director adds 61,750 shares through RSU settlements - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) counsel exercises 25,475 RSUs into shares - Stock Titan
Director at Stoke Therapeutics (STOK) sells 605 shares in plan trade - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down on Disappointing Earnings - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Needham Raises Price Target for Stoke Therapeutics (STOK) to $40 | STOK Stock News - GuruFocus
Stoke Therapeutics 2025 10-K: Advancing RNA-Based Medicines with TANGO Platform for Genetic Diseases - Minichart
Decoding Stoke Therapeutics Inc (STOK): A Strategic SWOT Insight - GuruFocus
Why Stoke Therapeutics (STOK) Is Down 11.4% After NEJM Data on Dravet Syndrome DrugAnd What's Next - simplywall.st
Stoke Therapeutics (NASDAQ:STOK) Issues Earnings Results, Misses Expectations By $0.22 EPS - MarketBeat
Stoke Therapeutics (NASDAQ: STOK) outlines Dravet Phase 3 plan and $165M Biogen alliance - Stock Titan
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Stoke Therapeutics Hits Day Low at $33 Amid Price Pressure - Markets Mojo
Granahan Investment Management LLC Sells 278,514 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Checkpoint Capital L.P. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc.Common Stock (NQ: STOK - The Chronicle-Journal
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.6% Following Insider Selling - MarketBeat
Aug Weekly: Can Stoke Therapeutics Inc grow without external fundingMarket Growth Review & Stock Market Timing Techniques - baoquankhu1.vn
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock - MarketBeat
Insider Sell: Adrian Krainer Sells 33,243 Shares of Stoke Therap - GuruFocus
Stoke Therapeutics Director Sells Over 33,000 Shares - TradingView
Stoke Therapeutics (STOK) chair exercises options, sells 4,355 shares under 10b5-1 plan - Stock Titan
Director at Stoke Therapeutics (STOK) sells 33K shares under 10b5-1 plan - Stock Titan
Stoke Earnings: Clinical Narrative Eclipses Financial Disclosure - Trefis
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Highs Report: Is Stoke Therapeutics Inc in a long term uptrendPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD By Investing.com - Investing.com Canada
Morgan Stanley Smith Barney files Rule 144 notice listing 58,769 and 31,739 STOK shares (STOK) - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week HighStill a Buy? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD - Investing.com
Stoke Therapeutics earnings in focus amid Dravet trial progress - Investing.com South Africa
Stoke Therapeutics earnings in focus amid Dravet trial progress By Investing.com - Investing.com India
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6%Still a Buy? - MarketBeat
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
A Look At Stoke Therapeutics (STOK) Valuation After NEJM Zorevunersen Dravet Syndrome Data Publication - simplywall.st
Stoke Therapeutics Hits New 52-Week High of $39.81, Up 146.41% - Markets Mojo
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Rhenman & Partners Asset Management AB Invests $5.88 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Can Stoke Therapeutics Inc. stock deliver sustainable ROE2026 WrapUp & Smart Allocation Stock Reports - Naître et grandir
Vanguard Group Inc. Buys 217,616 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rate Cut: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline - Yahoo Finance
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):